Champions Oncology Free Cash Flow (FCF) History (CSBR)
Champions Oncology reported −$5.0M in free cash flow for fiscal 2026, a decrease of $12.0M from the previous fiscal year, with a free cash flow margin of −8.47%.
View full Champions Oncology company overviewChampions Oncology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-04-30 | −$5.0M | −$12.0M | — | −8.47% |
| 2025 | 2025-04-30 | $7.0M | $14.0M | — | +12.29% |
| 2024 | 2024-04-30 | −$7.0M | −$8.1M | — | −13.90% |
| 2023 | 2023-04-30 | $1.1M | −$3.0M | −73.26% | +2.04% |
| 2022 | 2022-04-30 | $4.1M | $9.1M | — | +8.38% |
| 2021 | 2021-04-30 | −$5.0M | −$5.6M | — | −12.09% |
| 2020 | 2020-04-30 | $685,000 | −$343,000 | −33.37% | +2.13% |
| 2019 | 2019-04-30 | $1.0M | $3.5M | — | +3.80% |
| 2018 | 2018-04-30 | −$2.5M | $1.2M | — | −12.13% |
| 2017 | 2017-04-30 | −$3.6M | $3.1M | — | — |
| 2016 | 2016-04-30 | −$6.7M | $3.0M | — | — |
| 2015 | 2015-04-30 | −$9.7M | −$6.1M | — | — |
| 2014 | 2014-04-30 | −$3.7M | $682,000 | — | — |
| 2013 | 2013-04-30 | −$4.3M | $1.4M | — | — |
| 2012 | 2012-04-30 | −$5.7M | −$5.6M | — | — |
| 2011 | 2011-04-30 | −$139,000 | — | — | — |
Champions Oncology quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | −$2.2M | −$8.9M | — | −16.17% |
| Q3 2026 | 2026-01-31 | −$1.4M | −$1.8M | — | −8.31% |
| Q2 2026 | 2025-10-31 | −$2.0M | −$1.6M | — | −13.15% |
| Q1 2026 | 2025-07-31 | $554,000 | $243,000 | +78.14% | +3.96% |
| Q4 2025 | 2025-04-30 | $6.6M | $8.4M | — | +53.54% |
| Q3 2025 | 2025-01-31 | $448,000 | $1.5M | — | +2.63% |
| Q2 2025 | 2024-10-31 | −$377,000 | −$887,000 | — | −2.79% |
| Q1 2025 | 2024-07-31 | $311,000 | $5.0M | — | +2.21% |
| Q4 2024 | 2024-04-30 | −$1.8M | −$367,000 | — | −12.99% |
| Q3 2024 | 2024-01-31 | −$1.0M | −$1.8M | — | −8.41% |
| Q2 2024 | 2023-10-31 | $510,000 | −$2.2M | −80.98% | +4.41% |
| Q1 2024 | 2023-07-31 | −$4.7M | −$3.7M | — | −37.09% |
| Q4 2023 | 2023-04-30 | −$1.5M | −$1.7M | — | −11.11% |
| Q3 2023 | 2023-01-31 | $819,000 | −$3.0M | −78.74% | +6.41% |
| Q2 2023 | 2022-10-31 | $2.7M | $2.0M | +305.14% | +18.78% |
| Q1 2023 | 2022-07-31 | −$949,000 | −$258,000 | — | −6.90% |
| Q4 2022 | 2022-04-30 | $290,000 | $3.1M | — | +2.25% |
| Q3 2022 | 2022-01-31 | $3.9M | $4.9M | — | +29.20% |
| Q2 2022 | 2021-10-31 | $662,000 | $289,000 | +77.48% | +5.62% |
| Q1 2022 | 2021-07-31 | −$691,000 | $742,000 | — | −6.14% |
| Q4 2021 | 2021-04-30 | −$2.8M | −$3.5M | — | −26.83% |
| Q3 2021 | 2021-01-31 | −$1.1M | −$1.5M | — | −9.88% |
| Q2 2021 | 2020-10-31 | $373,000 | $240,000 | +180.45% | +3.69% |
| Q1 2021 | 2020-07-31 | −$1.4M | −$405,000 | — | −15.01% |
| Q4 2020 | 2020-04-30 | $658,000 | $547,000 | +492.79% | +7.52% |
| Q3 2020 | 2020-01-31 | $468,000 | −$535,000 | −53.34% | +5.19% |
| Q2 2020 | 2019-10-31 | $133,000 | $344,000 | — | +1.74% |
| Q1 2020 | 2019-07-31 | −$1.0M | −$1.2M | — | −15.26% |
| Q4 2019 | 2019-04-30 | $111,000 | $314,000 | — | +1.44% |
| Q3 2019 | 2019-01-31 | $1.0M | $633,000 | +171.08% | +15.60% |
| Q2 2019 | 2018-10-31 | −$211,000 | −$447,000 | — | −3.15% |
| Q1 2019 | 2018-07-31 | $125,000 | $3.0M | — | +2.01% |
| Q4 2018 | 2018-04-30 | −$203,000 | $215,000 | — | −4.12% |
| Q3 2018 | 2018-01-31 | $370,000 | $1.2M | — | +7.28% |
| Q2 2018 | 2017-10-31 | $236,000 | $133,000 | +129.13% | +4.54% |
| Q1 2018 | 2017-07-31 | −$2.9M | −$402,000 | — | −56.79% |
| Q4 2017 | 2017-04-30 | −$418,000 | $283,000 | — | — |
| Q3 2017 | 2017-01-31 | −$835,000 | $23,000 | — | — |
| Q2 2017 | 2016-10-31 | $103,000 | $2.7M | — | — |
| Q1 2017 | 2016-07-31 | −$2.5M | $116,000 | — | — |
| Q4 2016 | 2016-04-30 | −$701,000 | $1.3M | — | — |
| Q3 2016 | 2016-01-31 | −$858,000 | $1.5M | — | — |
| Q2 2016 | 2015-10-31 | −$2.6M | −$102,000 | — | — |
| Q1 2016 | 2015-07-31 | −$2.6M | $249,000 | — | — |
| Q4 2015 | 2015-04-30 | −$2.0M | −$2.1M | — | — |
| Q3 2015 | 2015-01-31 | −$2.4M | −$644,000 | — | — |
| Q2 2015 | 2014-10-31 | −$2.5M | −$2.7M | — | — |
| Q1 2015 | 2014-07-31 | −$2.8M | −$637,000 | — | — |
| Q4 2014 | 2014-04-30 | $55,000 | $1.2M | — | — |
| Q3 2014 | 2014-01-31 | −$1.7M | −$1.2M | — | — |
| Q2 2014 | 2013-10-31 | $206,000 | $963,000 | — | — |
| Q1 2014 | 2013-07-31 | −$2.2M | −$359,000 | — | — |
| Q4 2013 | 2013-04-30 | −$1.2M | $489,000 | — | — |
| Q3 2013 | 2013-01-31 | −$585,000 | $39,000 | — | — |
| Q2 2013 | 2012-10-31 | −$757,000 | $1.1M | — | — |
| Q1 2013 | 2012-07-31 | −$1.8M | −$195,000 | — | — |
| Q4 2012 | 2012-04-30 | −$1.7M | −$1.1M | — | — |
| Q3 2012 | 2012-01-31 | −$624,000 | −$2.3M | — | — |
| Q2 2012 | 2011-10-31 | −$1.8M | −$1.1M | — | — |
| Q1 2012 | 2011-07-31 | −$1.6M | −$1.2M | — | — |
| Q4 2011 | 2011-04-30 | −$596,000 | — | — | — |
| Q3 2011 | 2011-01-31 | $1.7M | — | — | — |
| Q2 2011 | 2010-10-31 | −$755,000 | — | — | — |
| Q1 2011 | 2010-07-31 | −$456,000 | — | — | — |
Champions Oncology free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$5.0M to −$5.0M, a net decrease of $74,000. Champions Oncology's latest reported quarter, Q4 2026, generated −$2.2M in free cash flow, a decrease of $8.9M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Champions Oncology filings at SEC.gov ↗